NCT05760261View on ClinicalTrials.gov

Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years

PHASE1CompletedINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

April 11, 2023

Primary Completion Date

August 13, 2024

Study Completion Date

August 20, 2024

Conditions

Urinary Tract Infections

Interventions

DRUG

Midazolam

Midazolam will be administered.

DRUG

GSK3882347

GSK3882347 will be administered.

Trial Locations (1)

CB2 0GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY